Through our medicine donation program, Novartis supports LMICs in their efforts to treat patients for neglected diseases or life-threatening conditions, and to provide medicines in areas impacted by the COVID-19 pandemic, natural disasters and extreme poverty.

20 m

COVID-19 Response Fund to support communities around the world impacted by the pandemic (USD)

In March, Novartis announced a USD 20 million COVID-19 Response Fund to support communities around the world impacted by the pandemic. In total, 172 local projects across 81 countries have received funding.

For over 30 years, Novartis and the Novartis Foundation have been working with partners around the world to eliminate leprosy. Since 2000, Novartis has donated more than 68 million blister packs of multidrug therapy (MDT) valued at approximately USD 108 million through the WHO, helping to treat more than 7.3 million leprosy patients worldwide. In 2020, we renewed our pledge with the WHO to extend our MDT donation to 2025.

Novartis has also been donating Egaten to the WHO for the treatment of fascioliasis, or liver fluke, since 2005, helping to treat approximately 2 million patients in more than 30 countries. Fascioliasis infects more than 2.4 million people globally. Egaten is currently the only medicine for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines.

Our generics division, Sandoz, continued its collaboration with World Child Cancer, a global charity that aims to improve diagnosis and access to treatment for children with cancer in LMICs. Since our partnership began in 2016, 6 185 children have been diagnosed in Ghana, Mexico, Myanmar and the Philippines, and 7 116 healthcare professionals have received training. In 2020, our efforts focused on the Philippines, where we helped 137 children receive a diagnosis. In addition, 2 795 healthcare professionals were trained in cancer treatment and care for children. By 2025, the charity aims to reach 16 000 children a year.

Sandoz also works with Americares, a leading health-focused relief and development organization that aids people affected by poverty and disaster. It provides long-term assistance in five healthcare areas: maternal, newborn and child health; infectious diseases; health system strengthening; mental health; and hypertension and diabetes. In 2020, Sandoz donated products worth approximately USD 35 million to the organization.

Donations performance indicators


Patients reached (thousands)









Leprosy (WHO)1








CMLPath to Care™









Value USD (millions)4





World Child Cancer




Emergency relief3





In 2020, the leprosy program fully transitioned to the Global Health organization as one of the flagship programs and is also included in data reported in the Novartis Global Health table above.


Numbers of patients reached have been updated to reflect the new methodology used by the WHO and based on real-world evidence.


Monetary and product donations


Wholesale acquisition cost (WAC) plus logistics costs for some programs

As the COVID-19 pandemic struck, we took rapid action to help ensure our donations reached patients in need. When hydroxychloroquine was considered as a potential treatment for COVID-19, Sandoz committed to donate 130 million doses of the medicine to public and private partners worldwide, based on government requests. To support the COVID-19 effort, Sandoz also partnered with Direct Relief to donate packages of critical medications and supplies to intensive care units throughout the US.

CMLPath to Care™ is a unique global initiative that connects people living with chronic myeloid leukemia (CML) with effective treatments made available at no cost, professional medical capabilities, trained physicians and hands-on support. The initiative is implemented in countries most urgently in need of medicines, as identified by the Access to Medicine Index. The Max Foundation directs the initiative, while Novartis donates medicines and provides financial resources.

CMLPath to Care™ evolved out of the Glivec International Assistance Program (GIPAP), also a collaboration between Novartis and the Max Foundation, that began in 2002. The transition of GIPAP to CMLPath to Care™ began in 2017 and encompassed 63 countries; the program is now expanding to an additional 17 lower-income countries. In 2020, we reached almost 32 000 patients through CMLPath to Care™. Novartis has committed to providing USD 29 million in financial assistance through 2021 and supplying 150 million Glivec and Tasigna tablets. Since the beginning of our partnership with the Max Foundation in 2002, we have donated more than 100 million daily doses of CML treatments.

This collaboration has helped significantly raise the CML survival rate in LMICs. Published in The Lancet’s EClinicalMedicine journal in January 2020, a study by Boston University researchers showed that despite the challenges of delivering cancer care in LMICs, 89% of patients supported by GIPAP survived for at least five years – a rate comparable to patients in developed countries.